Journal of Southern Medical University ›› 2006, Vol. 26 ›› Issue (08): 1146-1148.

Previous Articles     Next Articles

Inhibition of promyelocytic leukemia gene by tazarotene in hyperproliferative epidermis of psoriasis

WANG Qiong-yu, YAN Hu-ling, LIU Ping, PENG Zhen-hui, TAN Sheng-shun Department of Dermatology, Second Hospital of Xi’an Jiaotong University, Xi’an 710004, China   

  1. 西安交通大学医学院附属二院皮肤科; 西安交通大学医学院附属二院皮肤科 陕西西安710004; 陕西西安710004;
  • Online:2006-08-20 Published:2006-08-20

Abstract: Objective To investigate the mechanism of tazarotene against active psoriasis vulgaris. Methods A randomized, controlled trial was conducted in 43 patients with active psoriasis vulgaris, who were divided into tazarotene and control groups. Promyelocytic leukemia (PML) mRNA in active psoriatic lesions before and 14 days after tazarotene treatment was detected by in situ hybridization. Results PML mRNA expression was detected not only in the basal layer (86.96%), but also in the suprabasal layers of the epidermis in the manner of focal expression (78.26%). After tazarotene treatment, virtually no PML mRNA expression could be detected in the psoriatic lesions (8.69% in the basal layer and 4.35% in the suprabasal layers). PML mRNA expression in the control group underwent no obvious changes during the observation. Conclusions Tazarotene may inhibit abnormal proliferation of keratinocytes through down-regulating PML gene expression in active psoriatic epidermis. 

CLC Number: